Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Glioma 2Glioblastoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Papillary renal cell carcinoma, sporadic 1Pancreatic Ductal Adenocarcinoma 1Osteoradionecrosis 1Mouth Neoplasms 1Melanoma 1Hereditary leiomyomatosis and renal cell cancer 1Hematopoietic and Lymphoid System Neoplasm 1Head and Neck Neoplasms 1Gliosarcoma 1Fallopian Tube Mucinous Adenocarcinoma 1Ependymoma 1Craniopharyngioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Specimen Handling 4lutetium Lu 177 dotatate 3gallium Ga 68 dotatate 3Magnetic Resonance Spectroscopy 3olaparib 2cabozantinib 2belzutifan 2Temozolomide 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 26-fluorodopamine 23-Iodobenzylguanidine 2tipifarnib 1talazoparib 1spartalizumab 1pembrolizumab 1pegfilgrastim 1lanreotide 1guadecitabine 1fluorodopa F 18 1fludarabine phosphate 1copper dotatate CU-64 1atezolizumab 1Stem Cell Transplantation 1Lutetium-177 1Lutetium 1Ipilimumab 1Interleukin-13 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × Contrast Media × 1 year × Clear all
NCT04394858 2026-05-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
46 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡